Modeling of Non-Small Cell Lung Cancer Volume Changes during CT-Based Image Guided Radiotherapy: Patterns Observed and Clinical Implications

Table 1

Individual patient, tumor, treatment, and tumor response characteristics. Patient IDs starting with an “L” had a long RT course while those starting with an “S” had a short one.

Patient; ID	Sex	Age	Pathology	Total dose; (Gy)	Fx.; (Gy)	BED10 (Gy)	Days to; finish RT	Chemo
L1	M	68	SCCA	75	2.5	93.8	46	No
L2	M	78	ACA	75	2.5	93.8	43	Yes*
L3	F	75	SCCA	75	2.5	93.8	44	No
L4	F	72	ACA	80	2.5 (50 Gy); 2 (30 Gy)	98.5	70	No
L5	M	69	ACA	66.6	1.8	78.6	55	No
S1	F	65	SCCA	50	10	100.0	12	No
S2	F	66	ACA	50	10	100.0	9	No
S3	F	68	other^†	50	10	100.0	9	No^‡
S4	F	61	NSCLC	50	10	100.0	11	No
S5	M	70	ACA	50	10	100.0	12	Yes^§
S6	M	85	ACA	50	10	100.0	12	No
S7	F	69	SCCA	50	10	100.0	12	No
S8	M	73	ACA	50	10	100.0	9	No
S10	F	74	NSCLC	50	10	100.0	9	No
S11	F	82	Other^#	50	10	100.0	11	No
S12	M	74	SCCA	50	10	100.0	9	No
S13	M	66	SCCA	50	10	100.0	9	No

Abbreviations:
ID: identifier; M: male; F: female; Fx.: daily fraction dose; BED₁₀: biologically effective dose, 𝛼/𝛽 ratio of 10; SCCA: squamous cell carcinoma; ACA: adenocarcinoma; NSCLC: nonsmall cell lung cancer, not otherwise specified; RT: radiotherapy; chemo: chemotherapy.
*Three cycles of neoadjuvant paclitaxel (200 mg/m²) and carboplatin (AUC 5).
^†Clinical history consistent with metastatic breast adenocarcinoma.
^‡Patient completed chemotherapy for breast cancer 5 months prior to radiotherapy.
§Biopsy proven recurrence after receiving 50 Gy in 2.5 Gy fractions. Received neoadjuvant, concurrent, and adjuvant erlotinib (150 mg) and bevacizumab (15 mg/kg) for this course of RT.
^#Atypical cells suspicious for malignancy; serial CTs, PET/CT SUV ≥ 2.5, and clinical history consistent with primary lung malignancy.